The androgen receptor (AR) is the most significant target for patients with metastatic
castration-resistant prostate cancer (mCRPC). There is now irrefutable evidence that the AR …

Background The standard treatment for non-metastatic castration sensitive prostate cancer
(nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the …

Background: Although immune checkpoint inhibitors (ICIs) and targeted therapies have
been widely used as adjuvant treatment for resected melanoma, the optimal therapy …

PSA-TRICOM is a therapeutic vaccine in late stage clinical testing in metastatic castration-
resistant prostate cancer (mCRPC). Samarium-153-ethylene diamine tetramethylene …

Purpose: Bone antiresorptive agents can significantly reduce bone turnover markers (BTM)
in patients with advanced cancer. We evaluated association of changes in BTMs with overall …

Objective In mCRPC patients treated with 223 Ra, a major issue is the validation of reliable
prognostic and predictive biomarkers to maximize clinical benefit and minimize toxicities and …

Over the past decade, drug development in oncology has shifted from cytotoxic agents to
drugs with new mechanisms of action, such as cancer immunotherapies, targeted …

This exploratory, post hoc analysis aimed to model circulating tumor DNA (ctDNA) dynamics
and predict disease progression in patients with treatment‐naïve locally …

Prostate cancer is one of the most common malignant cancers of the male genitourinary
system and has high morbidity and mortality. Currently, treatment modalities for localized …

Rationale and Objectives The aims of this study were to investigate the association between
8-week tumor volume decrease and survival in an independent cohort of epidermal growth …